Market Overview

Merck, GE Healthcare Announce Collaboration on Use of Imaging Biomarkers for Investigational BACE Inhibitor Program

Share:
Related MRK
OncoSec Shares Spike 17% After New Data Defended
White House 'Shenanigans' Represent A Buying Opportunity: Cramer
E&G Advisors, LP Buys BlackRock Multi-Sector Income Trust, AllianzGI Convertible & ... (GuruFocus)
Related GE
Mid-Day Market Update: Dow Surges Over 100 Points; DURECT Shares Plummet
Mid-Morning Market Update: Markets Open Higher; General Electric Earnings Miss Expectations
Three major takeaways from GE's earnings (Fox Business)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [^18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer's disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples.

Posted-In: News

 

Related Articles (GE + MRK)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...